tiprankstipranks
Trending News
More News >
Shattuck Labs (STTK)
NASDAQ:STTK
US Market
Advertisement

Shattuck Labs (STTK) AI Stock Analysis

Compare
211 Followers

Top Page

STTK

Shattuck Labs

(NASDAQ:STTK)

Rating:47Neutral
Price Target:
$1.00
▲(12.36% Upside)
Shattuck Labs' overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. However, the recent $103 million private placement funding provides a positive outlook, potentially stabilizing the company's financial position and supporting future growth. The stock's valuation remains a concern due to negative earnings and lack of dividend yield.
Positive Factors
Clinical Development
STTK is expected to transition to a clinical-stage company, which should support new interest in its first-in-class DR3 approach in inflammatory bowel disease.
Financial Stability
The company announced a financing that extends its cash runway into 2029.
Negative Factors
Analyst Rating
Analyst maintains a Hold Rating given the early stage of the company.
Financial Performance
The company reported a Q2 net loss of $12.5MM.

Shattuck Labs (STTK) vs. SPDR S&P 500 ETF (SPY)

Shattuck Labs Business Overview & Revenue Model

Company DescriptionShattuck Labs (STTK) is a clinical-stage biotechnology company that focuses on developing novel therapeutics for the treatment of cancer and autoimmune diseases. The company specializes in its proprietary ARC (Agonist Redirected Checkpoint) platform, which is designed to create dual-function fusion proteins that modulate immune responses. Shattuck Labs operates within the biotechnology and pharmaceutical sectors, aiming to address unmet medical needs through innovative biological therapies.
How the Company Makes MoneyShattuck Labs makes money primarily through the development and eventual commercialization of its therapeutic products. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, which may include licensing agreements, milestone payments, and royalties. Additionally, as its therapies progress through clinical trials and receive regulatory approval, Shattuck Labs anticipates earning revenue from product sales. The company's ability to secure funding through investments and grants also supports its research and development activities, contributing to its financial stability.

Shattuck Labs Financial Statement Overview

Summary
Shattuck Labs faces significant financial challenges with declining revenues, negative profitability, and operational inefficiencies. While the company maintains a strong cash position, it relies heavily on external financing. The biotechnology industry often involves high R&D costs, contributing to losses. Continued focus on revenue growth and managing operational costs is essential for improving financial health.
Income Statement
35
Negative
The company shows a significant decline in revenue growth over the years, with TTM revenue at $19.1 million compared to $30 million in 2021. Gross profit margin is negative, indicating high operating costs. Net profit margin remains negative, reflecting ongoing losses. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and a lack of profitability.
Balance Sheet
45
Neutral
The debt-to-equity ratio is low due to minimal debt, which is a positive aspect. However, the equity ratio has decreased over time, indicating a decline in financial stability. Return on equity is negative, reflecting persistent losses. The company maintains a strong cash position, although total assets have decreased, indicating potential liquidity concerns.
Cash Flow
50
Neutral
The operating cash flow to net income ratio is negative, reflecting cash outflows from operations. Free cash flow has improved slightly but remains negative, indicating an inability to generate sufficient cash to cover expenses. Positive financing cash flow suggests reliance on external funding to support operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue37.70M5.72M1.66M652.00K30.02M9.93M
Gross Profit14.67M1.89M-2.38M-2.72M28.64M-27.55M
EBITDA-62.15M-76.74M-87.92M-100.26M-43.89M-36.31M
Net Income-61.51M-75.41M-87.30M-101.94M-44.97M-36.60M
Balance Sheet
Total Assets64.37M91.05M159.56M205.32M298.58M348.99M
Cash, Cash Equivalents and Short-Term Investments50.47M72.99M130.63M161.28M268.80M335.45M
Total Debt2.02M3.41M4.20M4.90M0.000.00
Total Liabilities7.35M11.42M14.86M29.17M26.80M39.13M
Stockholders Equity57.02M79.63M144.71M176.16M271.79M309.86M
Cash Flow
Free Cash Flow-55.94M-60.57M-81.64M-106.11M-65.04M-34.39M
Operating Cash Flow-55.90M-60.52M-81.23M-94.50M-57.12M-33.66M
Investing Cash Flow45.78M-8.51M110.86M49.44M-10.44M-146.32M
Financing Cash Flow-106.00K787.00K48.62M171.00K1.93M330.87M

Shattuck Labs Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.89
Price Trends
50DMA
0.87
Positive
100DMA
0.92
Negative
200DMA
1.06
Negative
Market Momentum
MACD
0.03
Negative
RSI
51.29
Neutral
STOCH
73.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Neutral. The current price of 0.89 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.87, and below the 200-day MA of 1.06, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 51.29 is Neutral, neither overbought nor oversold. The STOCH value of 73.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STTK.

Shattuck Labs Risk Analysis

Shattuck Labs disclosed 55 risk factors in its most recent earnings report. Shattuck Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Shattuck Labs Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$35.33M-277.74%536.44%63.68%
51
Neutral
$7.77B-0.12-39.78%2.21%22.68%-1.42%
47
Neutral
$49.34M-73.39%-27.33%34.66%
47
Neutral
$40.12M-90.07%-32.55%-15.83%
41
Neutral
$35.97M-312.77%61.18%
36
Underperform
$40.89M-47.87%18.86%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
STTK
Shattuck Labs
0.89
-2.61
-74.57%
PYPD
PolyPid
3.48
0.08
2.35%
LVTX
LAVA Therapeutics
1.55
-0.34
-17.99%
XLO
Xilio Therapeutics
0.67
-0.23
-25.56%
ACRV
Acrivon Therapeutics, Inc.
1.32
-8.04
-85.90%

Shattuck Labs Corporate Events

Private Placements and Financing
Shattuck Labs Announces $103M Private Placement Funding
Positive
Aug 5, 2025

On August 5, 2025, Shattuck Labs announced an oversubscribed private placement expected to raise up to approximately $103 million, led by OrbiMed and other investors. The funds will support the clinical development of SL-325 through multiple Phase 2 trials for inflammatory bowel disease and potentially other autoimmune diseases, with operations funded into 2029. The private placement involves shares of common stock and pre-funded warrants, with the proceeds contingent on certain regulatory clearances and conditions.

Shareholder Meetings
Shattuck Labs Elects Directors, Approves Auditor at Meeting
Neutral
Jul 15, 2025

On July 10, 2025, Shattuck Labs, Inc. held its Annual Meeting of Stockholders where all director nominees were elected and the proposal to ratify KPMG LLP as the independent auditor was approved. The meeting involved voting on the election of Class II Director Nominees and the ratification of KPMG LLP, reflecting shareholder support for the company’s governance and financial oversight.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 14, 2025